Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics reported a 7% increase in the sale of nanochannel array flowcells, reaching 8,390 in 3Q25 compared to 7,835 in the same quarter of the previous year, indicating strong demand across key geographies, including a notable expansion in Japan. The company is poised for near-term growth due to a significant 47% increase in clinical lab fee schedule payments for OGM use in hematologic malignancies and constitutional genetic disorders, which may enhance revenue streams. Management has set ambitious revenue guidance for FY2026, projecting a range of $30-33 million, reflecting a potential topline growth of up to 16% as utilization among the core customer base continues to expand.

Bears say

Bionano Genomics experienced a decline in total revenue for 4Q25, reporting $8.0 million, which represents a 2.6% year-over-year decrease, raising concerns about the company's growth trajectory. The company faces multiple risks that could hinder its financial performance, including lower-than-projected market uptake and utilization of its products, potential difficulties in securing additional capital for operations, and risks of shareholder dilution. Furthermore, a substantial net loss of $26.4 million, translating to a loss of $4.85 per share, underscores the financial challenges that could negatively impact investor confidence.

Bionano Genomics (BNGO) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Bionano Genomics (BNGO) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.